A bipartisan group of congressional lawmakers is urging the Trump administration to take action against the sale of illicit, compounded GLP-1 products. In a letter addressed to Food and Drug Administration (FDA) Commissioner, the lawmakers expressed their concern over the potential fraud and danger these products pose to consumers.
The letter, written by North Carolina Representatives Brad Knott (R) and Deborah Ross (D), highlights the growing issue of compounded GLP-1 products being sold without proper regulation or oversight. GLP-1 products are used to treat diabetes and are regulated by the FDA to ensure safety and efficacy. However, compounded versions of these drugs are often made by pharmacies without FDA approval, raising serious concerns about their quality and effectiveness.
The bipartisan group of lawmakers is calling for immediate action to address this issue, as they fear that consumers may be unknowingly purchasing fraudulent and potentially harmful products. In their letter, they emphasize the need for the FDA to step in and enforce regulations to protect the public from these dangerous products.
Representative Knott, a Republican, stated, “As a former pharmacist, I understand the importance of proper regulation and oversight when it comes to medication. Compounded GLP-1 products are not subject to the same rigorous standards as FDA-approved drugs, and this puts consumers at risk. It is our duty to ensure the safety and well-being of the American people, and we must take action to address this issue.”
His sentiments were echoed by Representative Ross, a Democrat, who added, “The sale of illicit, compounded GLP-1 products is a serious concern that must be addressed. Consumers have the right to know what they are putting into their bodies and should not have to worry about the safety and effectiveness of their medication. The FDA must take swift action to protect the public from these potentially fraudulent products.”
The lawmakers are also calling for increased transparency in the sale of compounded GLP-1 products. They are urging the FDA to require pharmacies to clearly label these products as “not FDA-approved” and to provide information on potential risks and side effects. This will help consumers make informed decisions about their medication and avoid potential harm.
The FDA has a crucial role to play in ensuring the safety and efficacy of medications in the United States. The bipartisan group of lawmakers is confident that the agency will take their concerns seriously and take necessary steps to address the issue of compounded GLP-1 products.
In conclusion, the bipartisan effort by Representatives Knott and Ross to address the sale of illicit, compounded GLP-1 products is a commendable step towards protecting the public from potential harm. The FDA must take swift and decisive action to regulate these products and ensure the safety and well-being of consumers. It is our hope that this issue will be resolved promptly, and consumers can have confidence in the medications they are taking.
